About Sai Sridhar Pharma Private Limited
Data last updated:
Sai Sridhar Pharma Private Limited is a private limited company based in Hyderabad, Telangana, India, a subsidiary of Nova Sud Pharmaceuticals Private Limited. It operates in the pharmaceutical retail and distribution segment of the pharmaceuticals sector. It was incorporated on 12 October 2007 and has been in existence for over 19 years.
The company is registered with the Registrar of Companies (ROC), Hyderabad, under CIN U24232TG2007PTC055902. Its GSTIN is 36AALCS7507A2ZF (Telangana). The company holds 4 GST registrations, of which 3 are active.
The company has an authorised share capital of ₹2.5 Lakh and a paid-up capital of ₹2.39 Lakh. It is led by directors including Phani Srinivas Ramella and Paidiwar Srinivas.
Its last annual general meeting (AGM) was held on 05 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Plot No : 5 First Floor Opp : Idpl Company Balanagar, Hyderabad, Telangana, India – 500037.
As per the financials filed for FY 2025, the company reported a revenue of ₹349.28 Cr, a decline of 21% compared to the previous year. For the same year it recorded a net profit of ₹1.07 Cr (net margin 0.3%) and EBITDA of ₹2.08 Cr (EBITDA margin 0.6%). Revenue has grown at a compounded annual rate (CAGR) of 2% over three years and 10% over five years.
The company has about 21 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Sai Sridhar Pharma. The company has 2 deals on record (1 funding round, 1 secondary share transfer), with disclosed funding of ₹25 Lakh; the latest was in March 2012. Its 10 peer companies in the Pharma industry (Pharma Retail and Distribution) are compared by revenue, 5 larger and 5 smaller; the largest is R S M Pharma Private Limited with revenue of ₹363.29 Cr.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website ssppltd.com.
CIN History of Sai Sridhar Pharma Private Limited
Sai Sridhar Pharma has one previous CIN (Corporate Identification Number): U24232AP2007PTC055902. The current CIN is U24232TG2007PTC055902, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24232TG2007PTC055902 | Current |
| U24232AP2007PTC055902 | Previous |
- EmailLocked
- TelephoneLocked
- Website
- Social MediaLocked
- Registered AddressPlot No : 5 First Floor Opp : Idpl Company Balanagar, Hyderabad, Telangana, India – 500037
- IndustryPharma, Pharmaceutical Retailers & Distributors
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Associated Brands with Sai Sridhar Pharma Private Limited
Sai Sridhar Pharma operates one associated brand: Sai Sridhar Pharma. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Operates as a pharmaceutical distributor supplying medical products. | ssppltd.com |
Business Activity of Sai Sridhar Pharma Private Limited
The main business activity of Sai Sridhar Pharma is trade. In detail, this covers wholesale trading.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading | Locked |
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Financials of Sai Sridhar Pharma Private Limited FY 2025 filings available
Sai Sridhar Pharma Private Limited reported revenue of ₹349.28 Cr (down 21% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR) of Sai Sridhar Pharma Private Limited
Revenue fell 21% in the latest year, but over five years it has grown at a compounded annual rate (CAGR) of 10%. EBITDA fell 28% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary of Sai Sridhar Pharma Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | •••• | •••• | •••• | •••• | •••• |
| Other Income | •••• | •••• | •••• | •••• | •••• |
| Total Revenue | •••• | •••• | •••• | •••• | •••• |
| Cost of Materials Consumed | •••• | •••• | •••• | •••• | •••• |
| Employee Benefit Expense | •••• | •••• | •••• | •••• | •••• |
| Finance Costs | •••• | •••• | •••• | •••• | •••• |
| Depreciation and Amortisation | •••• | •••• | •••• | •••• | •••• |
| Other Expenses | •••• | •••• | •••• | •••• | •••• |
| Total Expenses | •••• | •••• | •••• | •••• | •••• |
| EBITDA | ₹2.08 Cr | •••• | •••• | •••• | •••• |
| Profit Before Tax | •••• | •••• | •••• | •••• | •••• |
| Tax Expense | •••• | •••• | •••• | •••• | •••• |
| Net Profit (PAT) | ₹1.07 Cr | •••• | •••• | •••• | •••• |
| Balance Sheet | |||||
| Share Capital | •••• | •••• | •••• | •••• | •••• |
| Reserves and Surplus | •••• | •••• | •••• | •••• | •••• |
| Net Worth (Total Equity) | •••• | •••• | •••• | •••• | •••• |
| Long-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Short-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Trade Payables | •••• | •••• | •••• | •••• | •••• |
| Total Liabilities | •••• | •••• | •••• | •••• | •••• |
| Fixed Assets | •••• | •••• | •••• | •••• | •••• |
| Investments | •••• | •••• | •••• | •••• | •••• |
| Inventories | •••• | •••• | •••• | •••• | •••• |
| Trade Receivables | •••• | •••• | •••• | •••• | •••• |
| Cash and Bank Balance | •••• | •••• | •••• | •••• | •••• |
| Total Assets | •••• | •••• | •••• | •••• | •••• |
Financial Ratios of Sai Sridhar Pharma Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 0.6% | •••• | •••• | •••• | •••• |
| Net Profit Margin | 0.3% | •••• | •••• | •••• | •••• |
| Return on Equity (ROE) | •••• | •••• | •••• | •••• | •••• |
| Return on Capital Employed (ROCE) | •••• | •••• | •••• | •••• | •••• |
| Return on Assets (ROA) | •••• | •••• | •••• | •••• | •••• |
| Liquidity and Debt | |||||
| Current Ratio | •••• | •••• | •••• | •••• | •••• |
| Quick Ratio | •••• | •••• | •••• | •••• | •••• |
| Debt-to-Equity Ratio | •••• | •••• | •••• | •••• | •••• |
| Interest Coverage Ratio | •••• | •••• | •••• | •••• | •••• |
| Efficiency and Growth | |||||
| Asset Turnover | •••• | •••• | •••• | •••• | •••• |
| Receivable Days | •••• | •••• | •••• | •••• | •••• |
| Payable Days | •••• | •••• | •••• | •••• | •••• |
| Inventory Days | •••• | •••• | •••• | •••• | •••• |
| Revenue Growth | •••• | •••• | •••• | •••• | •••• |
| Net Profit Growth | •••• | •••• | •••• | •••• | •••• |
Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of Sai Sridhar Pharma are in the company report.
Financial statements from 2015
Earlier years and trend charts are in the company report.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Board of Directors of Sai Sridhar Pharma Private Limited
Sai Sridhar Pharma has 4 current directors and 4 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Udaya Lakshmi Tadepalli Also directs: Venkata Krishna Enterprises Private Limited | Additional Director | 23 May 2023 | 3 Years 4 Months | Current |
| Phani Srinivas Ramella Also directs: Deccan Medisales Private Limited, Venkata Krishna Enterprises Private Limited, Medplus Insurance Brokers Private Limited and 3 more | Director | 15 Mar 2010 | 16 Years 7 Months | Current |
| Paidiwar Srinivas Also directs: Dureleg Manufacturing Private Limited, Wynclark Pharmaceuticals Private Limited, Deccan Medisales Private Limited and 5 more | Director | 16 Oct 2017 | 9 Years 0 Months | Current |
| Satya Murali Krishna Kammila Also directs: Dureleg Manufacturing Private Limited, Wynclark Pharmaceuticals Private Limited, Deccan Medisales Private Limited and 5 more | Director | 29 Sep 2021 | 5 Years 0 Months | Current |
Peer Comparison of Sai Sridhar Pharma Private Limited
Sai Sridhar Pharma Private Limited is compared with the companies closest to it by revenue in the Pharma industry (Pharma Retail and Distribution). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| R S M Pharma Private Limited | ₹363.29 Cr (FY 2025) | •••• | •••• | 6.0% | •••• | Bangalore, Karnataka, India |
| A M Pharmaceuticals (India) Private Limited | ₹359.11 Cr (FY 2025) | •••• | •••• | 6.0% | •••• | Thrissur, Kerala, India |
| Gsa Surgical & Medicines Private Limited | ₹358.65 Cr (FY 2025) | •••• | •••• | 28.0% | •••• | Kolkata, West Bengal, India |
| Galaxystar Pharma Distributors Private Limited | ₹357.78 Cr (FY 2025) | •••• | •••• | 25.0% | •••• | Mumbai, Maharashtra, India |
| Pangea Enterprises Private Limited | ₹353.08 Cr (FY 2025) | •••• | •••• | -3.0% | •••• | New Delhi, Delhi, India |
| Sai Sridhar Pharma Private Limited this company | ₹349.28 Cr (FY 2025) | •••• | •••• | -21.0% | •••• | Hyderabad, Telangana, India |
| VPD Medi India Private Limited | ₹349.1 Cr (FY 2025) | •••• | •••• | 53.0% | •••• | Ahmedabad, Gujarat, India |
| Thea Technologies Private Limited | ₹343.52 Cr (FY 2019) | •••• | •••• | 218.0% | •••• | Mumbai, Maharashtra, India |
| Abs Mercantiles Private Limited | ₹342.03 Cr (FY 2025) | •••• | •••• | 8.0% | •••• | Gurgaon, Haryana, India |
| Parkleton Private Limited | ₹339.03 Cr (FY 2025) | •••• | •••• | -1.0% | •••• | Delhi, India |
| Mankind Prime Labs Private Limited | ₹332.48 Cr (FY 2025) | •••• | •••• | 29.0% | •••• | New Delhi, Delhi, India |
Peers are the five companies nearest above and the five nearest below Sai Sridhar Pharma by revenue in the Pharma industry (Pharma Retail and Distribution), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Auditor Details of Sai Sridhar Pharma Private Limited
Sai Sridhar Pharma Private Limited is audited by G P H K and ASSOCIATES for the financial year 2023.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| G P H K and ASSOCIATES | Locked | Locked | Locked |
Complete auditor history
Appointment and cessation dates and past auditor changes are in the company report.
- Appointment status
- Appointment dates
- Cessation dates
- Auditor changes
Verified entity values are shown only after access is granted.
Ownership and Shareholding of Sai Sridhar Pharma Private Limited
Shareholding and ownership data
Promoter, institutional, public and beneficial ownership figures are in the company report.
- Ownership categories
- Historical changes
- Group structure
- FII and DII holdings
Verified entity values are shown only after access is granted.
Charges & Borrowings of Sai Sridhar Pharma Private Limited
Sai Sridhar Pharma Private Limited does not have any charges (loans) registered with the Registrar of Companies.
Deals & Funding of Sai Sridhar Pharma Private Limited
Sai Sridhar Pharma Private Limited has 2 deals on record (1 funding round, 1 secondary share transfer), with disclosed funding of ₹25 Lakh; the latest was in March 2012.
Deals on record (2 of 2)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Mar 2012 | Funding round | ₹25 Lakh | Investors: Nova Sud Pharmaceuticals Private Limited |
| Sep 2009 | Secondary share transfer | Undisclosed | Buyer: Nova Sud Pharmaceuticals Private Limited Seller: 2 individuals |
Full deal history
All 2 deals with amounts, valuations, instruments and every party are in the company report.
- Every funding round and share transfer
- Amounts and valuations
- Investors, buyers and sellers
- Instruments and deal dates
Verified entity values are shown only after access is granted.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Employees and EPFO Compliance at Sai Sridhar Pharma Private Limited
Sai Sridhar Pharma Private Limited has a workforce of 21 employees as of Apr 08, 2024.
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
Recent Activity on Sai Sridhar Pharma Private Limited
Sai Sridhar Pharma Private Limited has 8 board changes on record since 2010: 4 appointments and 4 cessations. The latest: Udaya Lakshmi Tadepalli was appointed as Additional Director on 23 May 2023.
Credit Ratings, Litigation & Regulatory Alerts for Sai Sridhar Pharma Private Limited
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Sai Sridhar Pharma Private Limited
MSME payment history
Amounts due to small suppliers, the reasons given and MSME-1 filings are in the company report.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Sai Sridhar Pharma Private Limited
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Sai Sridhar Pharma Private Limited
Sai Sridhar Pharma has 4 GST registrations: 3 active and 1 cancelled or inactive.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 36AALCS7507A2ZF | Telangana | Active | 01 Jul 2017 |
| 36AALCS7507A3ZE | Telangana | Active | 21 Mar 2024 |
| 37AALCS7507A1ZE | Andhra Pradesh | Active | 01 Jul 2017 |
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Sai Sridhar Pharma Private Limited
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sai Sridhar Pharma Private Limited
Sai Sridhar Pharma is an active private limited company based in Hyderabad, Telangana, India. The company works in pharmaceutical retailers and distributors, within the pharma industry. It was incorporated on 12 October 2007 (19+ years old) and is registered under CIN U24232TG2007PTC055902.
Sai Sridhar Pharma reported revenue of ₹349.28 Cr for FY 2025 (down 21% YoY).
Sai Sridhar Pharma has 4 current directors:
- Udaya Lakshmi Tadepalli - Additional Director
- Phani Srinivas Ramella - Director
- Paidiwar Srinivas - Director
- Satya Murali Krishna Kammila - Director
Sai Sridhar Pharma reported a net profit of ₹1.07 Cr (net margin 0.3%) and EBITDA of ₹2.08 Cr (EBITDA margin 0.6%) for FY 2025, as per its filed financial statements.
The compounded annual growth rate (CAGR) of the revenue of Sai Sridhar Pharma is 2% over three years and 10% over five years. In the latest year (FY 2025) revenue fell 21%. CAGR is the steady yearly rate that links the first and the last year.
The GSTIN of Sai Sridhar Pharma is 36AALCS7507A2ZF, registered in Telangana. The company has 4 GST registrations in all, of which 3 are active and 1 is cancelled or inactive. Other active GSTINs include 36AALCS7507A3ZE (Telangana), 37AALCS7507A1ZE (Andhra Pradesh).
The CIN (Corporate Identification Number) of Sai Sridhar Pharma is U24232TG2007PTC055902. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Sai Sridhar Pharma was incorporated on 12 October 2007, making it 19+ years old. It is registered with the Registrar of Companies, Hyderabad.
Sai Sridhar Pharma has 2 deals on record (1 funding round, 1 secondary share transfer), with disclosed funding of ₹25 Lakh; the latest was in March 2012.
The peers of Sai Sridhar Pharma by revenue are R S M Pharma Private Limited, A M Pharmaceuticals (India) Private Limited, Gsa Surgical & Medicines Private Limited, Galaxystar Pharma Distributors Private Limited, Pangea Enterprises Private Limited and 5 more, all in the Pharma industry (Pharma Retail and Distribution).
Udaya Lakshmi Tadepalli was appointed as Additional Director on 23 May 2023. Satya Murali Krishna Kammila was appointed as Director on 29 Sep 2021. Paidiwar Srinivas ceased to be Additional Director on 30 Sep 2018. Sai Sridhar Pharma has 8 board changes on record in total.